Studies on the Metabolic Fate of Semotiadil Fumarate (SD-3211) I: Absorption, Distribution, Metabolism and Excretion after Single Administration to Male Rats.

Morikawa, Nobuo; Takashina, Hideo; Ibuki, Hajime; Matsuoka, Hidehito; Yamaguchi, Hidefumi; Miyagi, Syogo; Horiuchi, Masato

doi:10.2133/dmpk.7.315

Search citation statements

Order By: Relevance

Paper Sections

Select...

Metabolism: Absorption Metabolic Fate and Excretion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1996

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6A shows the proposed metabolic fate of semotiadil given orally (p.0.) to male rats (43). ['4C]Semotiadil (10 mg/kg) was absorbed mainly in the duodenum, jenunum, and ileum, and was rapidly metabolized in the liver.…”

Section: Metabolism: Absorption Metabolic Fate and Excretionmentioning

confidence: 99%

Pharmacological Profile and Therapeutic Perspectives of Semotiadil Fumarate (SD‐3211), a Novel Benzothiazine Ca²⁺ Antagonist

Nakayama

1996

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Antagonist--Ca2+ Channel-Semotiadil. Semotiadil fumarate {( + )-(R)-32-[5-methoxy-2-[3-[methy1[2-[3,4-(methylenedioxy)phenoxy]-ethyl]amino]propoxy]phenyl-W-1,4-benzothiazin-3(4H)-one hydrogen fumarate, or SD-321 l}, shown in Fig. 1, is a novel Ca2+ antagonist with a benzothiazine ring (8,26). Semotiadil exerts potent and long-lasting Ca'+ antagonistic actions, as shown by the results of in vitro and in vivo experiments. Semotiadil had intermediate tissue selectivities:it is more vasoselective than diltiazem and verapamil and more cardioselective than nifedipine. Semotiadil has been called a "second generation of

show abstract

Section: Metabolism: Absorption Metabolic Fate and Excretionmentioning

confidence: 99%

Pharmacological Profile and Therapeutic Perspectives of Semotiadil Fumarate (SD‐3211), a Novel Benzothiazine Ca²⁺ Antagonist

Nakayama

1996

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

show abstract

Studies on the Metabolic Fate of Semotiadil Fumarate (SD-3211) I: Absorption, Distribution, Metabolism and Excretion after Single Administration to Male Rats.

Cited by 1 publication

References 3 publications

Pharmacological Profile and Therapeutic Perspectives of Semotiadil Fumarate (SD‐3211), a Novel Benzothiazine Ca²⁺ Antagonist

Pharmacological Profile and Therapeutic Perspectives of Semotiadil Fumarate (SD‐3211), a Novel Benzothiazine Ca²⁺ Antagonist

Contact Info

Product

Resources

About

Studies on the Metabolic Fate of Semotiadil Fumarate (SD-3211) I: Absorption, Distribution, Metabolism and Excretion after Single Administration to Male Rats.

Cited by 1 publication

References 3 publications

Pharmacological Profile and Therapeutic Perspectives of Semotiadil Fumarate (SD‐3211), a Novel Benzothiazine Ca2+ Antagonist

Pharmacological Profile and Therapeutic Perspectives of Semotiadil Fumarate (SD‐3211), a Novel Benzothiazine Ca2+ Antagonist

Contact Info

Product

Resources

About

Pharmacological Profile and Therapeutic Perspectives of Semotiadil Fumarate (SD‐3211), a Novel Benzothiazine Ca²⁺ Antagonist

Pharmacological Profile and Therapeutic Perspectives of Semotiadil Fumarate (SD‐3211), a Novel Benzothiazine Ca²⁺ Antagonist